Overcoming the Blood-brain Barrier in Neurodegenerative Disorders and Brain Tumours

Overview

Journal IET Nanobiotechnol

Publisher Wiley

Specialty Biotechnology

Date 2020 Aug 7

PMID 32755952

Citations 8

Authors

Zahra Ebrahimi

Sam Talaei

Shahin Aghamiri

Nasser Hashemi Goradel

Ali Jafarpour

Babak Negahdari

Affiliations

Soon will be listed here.

Abstract

Drug delivery is one of the major challenges in the treatment of central nervous system disorders. The brain needs to be protected from harmful agents, which are done by the capillary network, the so-called blood-brain barrier (BBB). This protective guard also prevents the delivery of therapeutic agents to the brain and limits the effectiveness of treatment. For this reason, various strategies have been explored by scientists for overcoming the BBB from disruption of the BBB to targeted delivery of nanoparticles (NPs) and cells and immunotherapy. In this review, different promising brain drug delivery strategies including disruption of tight junctions in the BBB, enhanced transcellular transport by peptide-based delivery, local delivery strategies, NP delivery, and cell-based delivery have been fully discussed.

Citing Articles

Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.

Shadab A, Farokhi S, Fakouri A, Mohagheghzadeh N, Noroozi A, Razavi Z Eur J Med Res. 2025; 30(1):71.

PMID: 39905470 PMC: 11792566. DOI: 10.1186/s40001-025-02310-2.

Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target.

Puranik N, Song M Molecules. 2024; 29(23).

PMID: 39683904 PMC: 11643865. DOI: 10.3390/molecules29235744.

Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.

Blanchard R, Adjei I RSC Adv. 2023; 13(45):31411-31425.

PMID: 37901257 PMC: 10603567. DOI: 10.1039/d3ra01153d.

FUS-mediated blood-brain barrier disruption for delivering anti-Aβ antibodies in 5XFAD Alzheimer's disease mice.

Antoniou A, Stavrou M, Evripidou N, Georgiou E, Kousiappa I, Koupparis A J Ultrasound. 2023; 27(2):251-262.

PMID: 37516718 PMC: 11178731. DOI: 10.1007/s40477-023-00805-4.

Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives.

Ouaamari Y, Van den Bos J, Willekens B, Cools N, Wens I Int J Mol Sci. 2023; 24(4).

PMID: 36835277 PMC: 9968045. DOI: 10.3390/ijms24043866.

References

Wu L, Li X, Janagam D, Lowe T . Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors. Pharm Res. 2013; 31(3):531-40. DOI: 10.1007/s11095-013-1196-z. View

Wang J, Al-Jamal K . Functionalized carbon nanotubes: revolution in brain delivery. Nanomedicine (Lond). 2015; 10(17):2639-42. DOI: 10.2217/nnm.15.114. View

Yang Z, Li J, Wang Z, Dong D, Qi X . Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014; 35(19):5226-39. DOI: 10.1016/j.biomaterials.2014.03.017. View

Abou Al-Shaar H, Alkhani A . Intrathecal baclofen therapy for spasticity: A compliance-based study to indicate effectiveness. Surg Neurol Int. 2016; 7(Suppl 19):S539-41. PMC: 4982341. DOI: 10.4103/2152-7806.187529. View

Chen B, Cheng Q, Yang K, Lyden P . Thrombin mediates severe neurovascular injury during ischemia. Stroke. 2010; 41(10):2348-52. DOI: 10.1161/STROKEAHA.110.584920. View

Wolfe D, Mata M, Fink D . A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther. 2009; 16(4):455-60. PMC: 2683467. DOI: 10.1038/gt.2009.17. View

Chen Z, Strickland S . Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1998; 91(7):917-25. DOI: 10.1016/s0092-8674(00)80483-3. View

Black K, Chio C . Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. Neurol Res. 1992; 14(5):402-4. DOI: 10.1080/01616412.1992.11740093. View

Pardeshi C, Belgamwar V . Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013; 10(7):957-72. DOI: 10.1517/17425247.2013.790887. View

10.

Argaw A, Gurfein B, Zhang Y, Zameer A, John G . VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A. 2009; 106(6):1977-82. PMC: 2644149. DOI: 10.1073/pnas.0808698106. View

11.

Hendricks B, Cohen-Gadol A, Miller J . Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Neurosurg Focus. 2015; 38(3):E10. DOI: 10.3171/2015.1.FOCUS14767. View

12.

Ford J, Osborn C, Barton T, Bleehen N . A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer. 1999; 34(11):1807-11. DOI: 10.1016/s0959-8049(98)00155-5. View

13.

Choi C, Alabi C, Webster P, Davis M . Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010; 107(3):1235-40. PMC: 2824286. DOI: 10.1073/pnas.0914140107. View

14.

Voigt N, Henrich-Noack P, Kockentiedt S, Hintz W, Tomas J, Sabel B . Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. Eur J Pharm Biopharm. 2014; 87(1):19-29. DOI: 10.1016/j.ejpb.2014.02.013. View

15.

Boockvar J, Tsiouris A, Hofstetter C, Kovanlikaya I, Fralin S, Kesavabhotla K . Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2010; 114(3):624-32. PMC: 3622705. DOI: 10.3171/2010.9.JNS101223. View

16.

Sharma U, Sharma A, Chau R, Straubinger R . Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res. 1997; 14(8):992-8. DOI: 10.1023/a:1012136925030. View

17.

Neuwelt E, GLASBERG M, Frenkel E, Barnett P . Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol. 1983; 14(3):316-24. DOI: 10.1002/ana.410140310. View

18.

Nakano S, Matsukado K, Black K . Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res. 1996; 56(17):4027-31. View

19.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

20.

Cloughesy T, Black K, Gobin Y, Farahani K, Nelson G, Villablanca P . Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery. 1999; 44(2):270-8; discussion 278-9. DOI: 10.1097/00006123-199902000-00015. View